ANDOVER, Mass., Oct. 15, 2024 /PRNewswire/ -- TransMedics Group, Inc. ("TransMedics") (Nasdaq: TMDX), a medical technology company that is transforming organ transplant therapy for patients with endstage lung, heart and liver failure, today announced that it will release financial results for the third quarter 2024 after market close on Monday, October 28, 2024. The TransMedics management team will host a corresponding conference call beginning at 4:30 p.m. ET / 1:30 p.m. PT. Investors interested in listeni ...

Overview of FMR LLC (Trades, Portfolio)'s Recent Transaction On September 30, 2024, FMR LLC (Trades, Portfolio) executed a significant transaction involving the sale of 2,281,896 shares of TransMedics Group Inc (TMDX, Financial), a leader in advanced organ transplant technology. This move reduced FMR LLC (Trades, Portfolio)'s holdings in the company by 50.82%, leaving them with a total of 2,208,308 shares. The shares were traded at a price of $157 each, reflecting a strategie adjustment in FMR LLC (Trades, ...

TransMedics (TMDX) closed the last trading session at $143.80, gaining 0.3% over the past four weeks, but there could be plenty of upside left in the stock if short-term price targets set by Wall Street analysts are any guide. The mean price target of $181.89 indicates a 26.5% upside potential. The average comprises nine short-term price targets ranging from a low of $153 to a high of $208, with a standard deviation of $17.60. While the lowest estimate indicates an increase of 6.4% from the current price le ...

TransMedics (TMDX) shares rallied 10.1% in the last trading session to close at $159.14. This move can be attributable to notable volume with a higher number of shares being traded than in a typical session. This compares to the stock's 13.3% loss over the past four weeks. TransMedics scored a strong price increase driven by investors' optimism following the news of the company joining the S&P SmallCap 600. On Sept. 26, per S&P Dow Jones' press release, Transmedics will replace The Ensign Group in the S&P S ...

sturti Investment Thesis TransMedics (NASDAQ:TMDX) is a company that is revolutionizing the way organs are transported for transplants. This is a statement that puts a lot of weight on the company, but so far, it has proven to be true and sales continue to grow +100% YoY with net margins of 10 to 12%. Despite strong competitive advantages, TMDX is trading at less than 11 times EV/Sales, while recently acquired companies and some competitors are trading at more than 17 times, making it a buying opportunity. ...

TransMedics' revolutionary Organ Care System, high sales growth, and newfound profitability combine with its towering valuation to create wild volatility. Shares of TransMedics (TMDX -5.03%), a leader in heart, lung, and liver transplant technologies, have plummeted 15% in the past week as of 4 p.m. ET Thursday, according to data provided by S&P Global Market Intelligence. While no specific news led to the company's drop, the movement is probably tied to the stock's increasing volatility following a remarka ...

Momentum investing is all about the idea of following a stock's recent trend, which can be in either direction. In the 'long' context, investors will essentially be "buying high, but hoping to sell even higher." And for investors following this methodology, taking advantage of trends in a stock's price is key; once a stock establishes a course, it is more than likely to continue moving in that direction. The goal is that once a stock heads down a fixed path, it will lead to timely and profitable trades. Whi ...

Last week, the Dow Jones Industrial Average and the S&P 500 gained a marginal 0.7% and 0.5%, respectively. The Nasdaq Composite's gain was also negligible. Investors adopted a cautious approach last week before the annual Jackson Hole Economic Policy Symposium event that concluded on Aug 24, 2024. The broader markets moved sideways. U.S. Federal Reserve Chairman Jerome Powell, in his keynote speech, talked about imminent policy easing after holding the key lending rate at a two-decade high for more than a y ...

ANDOVER, Mass., Aug. 21, 2024 /PRNewswire/ -- TransMedics Group, Inc. ("TransMedics") (Nasdaq: TMDX), a medical technology company that is transforming organ transplant therapy for patients with endstage lung, heart, and liver failure, today announced that members of the management team will participate in a fireside chat at the upcoming Morgan Stanley 22nd Annual Global Healthcare Conference at the Marriott Marquis New York. The fireside chat will take place on Wednesday, September 4, 2024, at 1:05 p.m. Ea ...

Shares of TransMedics (TMDX) have been strong performers lately, with the stock up 12% over the past month. The stock hit a new 52-week high of $175.73 in the previous session. TransMedics has gained 111.7% since the start of the year compared to the 10.1% move for the Zacks Medical sector and the 8.3% return for the Zacks Medical - Instruments industry. What's Driving the Outperformance? The stock has a great record of positive earnings surprises, as it hasn't missed our earnings consensus estimate in any ...